Accessibility Menu
 
Cellectis logo

Cellectis

(NASDAQ) CLLS

Current Price$3.09
Market Cap$222.76M
Since IPO (2015)-92%
5 Year-84%
1 Year+137%
1 Month-26%

Cellectis Financials at a Glance

Market Cap

$222.76M

Revenue (TTM)

$73.17M

Net Income (TTM)

$67.57M

EPS (TTM)

$-0.68

P/E Ratio

-4.55

Dividend

$0.00

Beta (Volatility)

1.36 (Average)

Price

$3.09

Volume

657

Open

$3.13

Previous Close

$3.09

Daily Range

$3.09 - $3.13

52-Week Range

$1.10 - $5.48

CLLS: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Cellectis

Industry

Biotechnology

Employees

229

CEO

André Choulika, PhD

Headquarters

Paris, 75013, FR

CLLS Financials

Key Financial Metrics (TTM)

Gross Margin

84%

Operating Margin

-48%

Net Income Margin

-93%

Return on Equity

-66%

Return on Capital

-19%

Return on Assets

-21%

Earnings Yield

-21.98%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$222.76M

Shares Outstanding

72.33M

Volume

657

Short Interest

0.00%

Avg. Volume

48.23K

Financials (TTM)

Gross Profit

$53.05M

Operating Income

$40.48M

EBITDA

$20.36M

Operating Cash Flow

$40.14M

Capital Expenditure

$2.37M

Free Cash Flow

$42.50M

Cash & ST Invst.

$208.66M

Total Debt

$119.90M

Cellectis Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$10.62M

-16.5%

Gross Profit

$5.29M

-48.1%

Gross Margin

49.80%

N/A

Market Cap

$222.76M

N/A

Market Cap/Employee

$1.03M

N/A

Employees

216

N/A

Net Income

$26.30M

-544.1%

EBITDA

$116.80K

-100.8%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$88.76M

-47.4%

Accounts Receivable

$22.20M

-3.6%

Inventory

$0.00

N/A

Long Term Debt

$101.74M

+30.0%

Short Term Debt

$18.16M

+37.3%

Return on Assets

-20.89%

N/A

Return on Invested Capital

-19.41%

N/A

Free Cash Flow

$10.95M

-511.2%

Operating Cash Flow

$10.47M

-22183.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SLNSilence Therapeutics plc
$4.93-7.16%
ACIUAC Immune S.A.
$2.70-6.57%
AMRNAmarin Corporation plc
$14.45-1.50%
ALDXAldeyra Therapeutics, Inc.
$1.77-3.80%

Trending Stocks

Symbol / CompanyPricePrice Chg
TQQQProShares Trust - ProShares UltraPro Qqq
$38.78-0.06%
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$8.28+0.05%
QQQInvesco QQQ Trust
$562.58-0.02%
ARTLArtelo Biosciences
$10.54+2.30%

Questions About CLLS

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.